Careers  |  Sign In  |  Register  |   Twitter

Latest in Hematology-Oncology

Current therapeutic options for non-small cell lung cancer (NSCLC) are ever-evolving with the possibility of solely immunotherapy-based treatment regimens on the near horizon for certain patients.
Adeno-associated virus (AAV) vectors are frequently utilized as viral vectors for gene therapy.
For diagnosis 1 year after sample collection, the test detected mutations in 90% of patients.